Town Sports International Holdings, Inc. (NASDAQ:CLUB) net profit margin is 1.00% and weekly performance is 1.19%. On last trading day company shares ended up $5.97. Analysts mean target price for the company is $8.25. Town Sports International Holdings, Inc. (NASDAQ:CLUB) distance from 50-day simple moving average (SMA50) is -8.21%.
On June 20, 2014, Agile Therapeutics Inc (NASDAQ:AGRX)announced that patent U.S. 8,747,888 (‘888 Patent), was issued by the U.S. Patent and Trademark Office on June 10, 2014. The patent is a continuation of its prior patent US 8,246,978 and is intended to provide additional patent protection covering its contraceptive patch, Twirla™ ethinyl estradiol and levonorgestrel transdermal system. Agile Therapeutics Inc (NASDAQ:AGRX) shares advanced 3.10% in last trading session and ended the day on $10.65. AGRX return on assets is -177.60%.
On June 18, 2014, Quinpario Acquisition Corp (NASDAQ:QPAC) announced that it has increased the price it will offer to pay for its warrants in its previously announced warrant tender offer from $0.75 to $1.00 per warrant. The warrant tender offer is scheduled to expire at 11:59 p.m., New York City time, on July 7, 2014, unless extended or terminated. Quinpario Acquisition Corp (NASDAQ:QPAC) shares moved down -0.10% in last trading session and was closed at $10.27, while trading in range of $10.20 – $10.33. Quinpario Acquisition Corp (NASDAQ:QPAC) year to date (YTD) performance is 1.68%.
Park City Group, Inc. (NASDAQ:PCYG), a cloud-based software company that uses big data management to help retailers and their suppliers sell more, stock less and see everything, is showcasing ReposiTrak® food safety and its retail supply chain solutions at the FMI Connect 2014 in McCormick Place, Chicago, June 10-13, 2014. Park City Group, Inc. (NASDAQ:PCYG) ended the last trading day at $11.44. Company weekly volatility is calculated as 8.38% and price to cash ratio as 56.93. Park City Group, Inc. (NASDAQ:PCYG) showed a negative weekly performance of -13.98%.
IsoRay, Inc. (NYSEMKT:ISR) surged Tuesday after the company announced the world’s first liquid cesium-131 treatment for metastatic brain cancer. IsoRay reported the treatment of a brain tumor that had metastasized from esophageal cancer with the company’s liquid Cesium-131, also called Cesitrex, which recently received FDA clearance for internal radiation therapy. The treatment used GliaSite radiation therapy Balloon Catheter System, which delivers a high dose of radiation to an area and minimizes radiation exposure to healthy brain tissue. IsoRay, Inc. (NYSEMKT:ISR) ended the last trading day at $2.97. Company weekly volatility is calculated as 6.82% and price to cash ratio as 6.82. IsoRay, Inc. (NYSEMKT:ISR) showed a positive weekly performance of 20.73%.